Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NanoViricides Inc NNVC

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.


NYSEAM:NNVC - Post by User

Post by lelianicruzon Nov 25, 2024 2:04pm
47 Views
Post# 36329563

$NNVC is hitting new highs—jump in before it’s too late

$NNVC is hitting new highs—jump in before it’s too late

NanoViricides, Inc. (NNVC) is a clinical-stage biotech company leading the charge in the development of innovative antiviral therapeutics using its proprietary nanomedicine platform. The company specializes in the application of nanotechnology to treat viral infections, with a focus on creating targeted, efficient, and less toxic treatments. NanoViricides’ groundbreaking approach in nanomedicine has positioned the company as a key player in the biotechnology sector, with its portfolio attracting significant attention from both the medical community and investors.

Nanomedicine: A Revolutionary Approach to Viral Treatment

Nanomedicine involves using nanomaterials—materials with a size range of 1 to 100 nanometers—designed to interact with biological systems. This novel approach allows for precise targeting of viruses, potentially offering more effective and less harmful alternatives to traditional antiviral therapies. NanoViricides stands out in the antiviral drug development arena by utilizing nanotechnology to create antiviral agents that mimic the viral surface structures, effectively trapping the virus and preventing it from infecting healthy cells.

Unlike conventional antiviral treatments that focus on targeting specific proteins or enzymes within the virus, NanoViricides’ technology provides a broad-spectrum approach, targeting a wide range of viral pathogens. This versatility positions NanoViricides’ nanomedicine platform as a unique and potentially groundbreaking solution in the fight against viral diseases.

<< Previous
Bullboard Posts
Next >>